MRC Technology sells its melanocortin receptors programme to Pfizer Inc

The melanocortin receptors (MCRs) programme includes a set of small molecules and targets for these small molecules came from Mauro Perretti, Professor of Immunopharmacology at Queen Mary University of London (QMUL).

MRC Technology and Daiichi Sankyo collaborate to identify novel targets for drug discovery

MRC Technology has established a drug discovery collaboration with Daiichi Sankyo, a global pharmaceutical company with corporate origins in Japan. The agreement will focus on the identification and selection of novel drug targets with the potential to become potent and selective therapeutics including oncology, cardiovascular and metabolic diseases.

16 applications received for first Dementia Consortium deadline

The Dementia Consortium has got off to a great start, with 16 applications received for the first review deadline on 23 March. Of these, two have been asked to reapply with additional information and four have progressed to the second round of review, with decisions expected in July.

MRC Technology and Chinese Academy of Science extend collaboration to identify new targets for drug discovery

MRC Technology has extended its existing drug discovery collaboration with the Shanghai Institute of Biotechnology and Cell Biology (SIBCB), Chinese Academy of Sciences (CAS). MRC Technology will give SIBCB access to its unique compound library which will be used to screen novel targets derived from SIBCB research.

UCB and UK’s MRC Technology sign exclusive license agreement for a fibrosis programme

UCB and MRC Technology announced today that they have entered an exclusive license agreement, with UCB obtaining rights in a novel fibrosis therapy program. The program stems from a collaboration between MRC Technology’s Centre for Therapeutics Discovery and leading academics at the University of Sheffield on development of a novel antibody-based therapy which targets a key step in the progression of fibrosis.

£3m Dementia Consortium launched to boost dementia drug discovery

New Consortium unites charity, academic and private sectors in search for new treatments for dementia by supporting research into novel targets for neurodegeneration

MRC Technology to Oversee Parkinson’s UK Intellectual Property

MRC Technology will provide Parkinson's UK with support in oversight and management of intellectual property, allowing Parkinson's UK to maximise patient benefits and return on investment from their funded research.

MRC Technology and Oxford University Collaborate to Develop Novel Pain Therapeutics for Migraine

The collaboration will screen selective and potent potassium channel activators to develop novel therapeutic interventions in migraine. Drawing on MRC Technology’s commercialisation expertise in drug discovery, the project focuses on bringing to clinic more effective pain treatments arising from the work of Dr Cader’s group in identifying KCNK18, the first gene underlying typical migraine.

MRC Technology to join innovation network at Stevenage Bioscience Catalyst

The relocation of the Centre for Therapeutics Discovery. MRC Technology's drug discovery unit, will start the next step in campus growth, and is expected to be completed by 2015.